What is it about?
This publication explores the relationship of a set of genotypes of drug metabolizing enzymes to plasma clearance as well as most common adverse effect of a commonly used cytotoxic and immunosuppressive drug cyclophosphamide. It supports involvement of CYP2C19, ALDH3A1 and GSTA1 in this regard.
Featured Image
Why is it important?
This article explores the genetic basis of variation in breast cancer treatment.
Perspectives
Read the Original
This page is a summary of: Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients, European Journal of Clinical Pharmacology, October 2011, Springer Science + Business Media,
DOI: 10.1007/s00228-011-1134-0.
You can read the full text:
Contributors
The following have contributed to this page